Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction. (November 2018)

• Record Type: Journal Article
• Authors: Mouton, Alan J.; Rivera Gonzalez, Osvaldo J.; Kaminski, Amanda R.; Moore, Edwin T.; Lindsey, Merry L.
• Is Part Of: Pharmacological research. Volume 137(2018)
• Page Start: 252
• Page End: 258
• Publication Date: 2018-11
• Subjects: Inflammation -- Extracellular matrix -- Inflammation resolution -- Macrophage -- Neutrophil -- Fibroblast; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2018.10.026
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Following myocardial infarction (MI), timely resolution of inflammation promotes wound healing and scar formation while limiting excessive tissue damage. Resolution promoting factors (RPFs) are agents that blunt leukocyte trafficking and inflammation, promote necrotic and apoptotic cell clearance, and stimulate scar formation. Previously identified RPFs include mediators derived from lipids (resolvins, lipoxins, protectins, and maresins), proteins (glucocorticoids, annexin A1, galectin 1, and melanocortins), or gases (CO, H2 S, and NO). Matrix metalloproteinase-12 (MMP-12; macrophage elastase) has shown promising RPF qualities in a variety of disease states. We review here the evidence that MMP-12 may serve as a novel RPF with potential therapeutic efficacy in the setting of MI.